Cooley Boosts Patent Litigation Capabilities With Life Sciences Trio

June 5, 2023 – Chad Shear, Betsy Flanagan and Geoff Biegler have joined as partners in Cooley’s market-leading intellectual property litigation practice within the firm’s global litigation department. Arriving from Fish & Richardson, the group brings extensive trial experience, having successfully represented early- to late-stage life sciences companies in complex patent disputes across district and appellate courts, and the Patent Trial and Appeal Board.

“The addition of this team of first-rate litigators reflects Cooley’s commitment to the continued strategic growth of our patent litigation capabilities,” said Michael Attanasio, chair of Cooley’s global litigation department. “Their collective experience and track record of success in all forums make them an outstanding addition not only to our patent litigation and trial teams, but also to our best-in-class life sciences platform across the entire firm.”

“Chad, Betsy and Geoff have a long history of successfully representing industry-leading life sciences, biotechnology and pharmaceutical brands in high-stakes patent litigation involving core products – both in the US and internationally,” said Stephen Smith, chair of Cooley’s IP litigation practice. “We are thrilled to welcome this formidable trio to our growing practice – they will be a huge asset to our deep bench of patent litigators and trial lawyers.”

Shear, Flanagan and Biegler represent life sciences companies in make-or-break patent infringement disputes, with a focus on branded Hatch-Waxman litigation, competitor small and large molecule drug cases, and Biologics Price Competition and Innovation Act litigation. In addition to providing clients with strategic portfolio advice, the team routinely leads global litigation to harmonize approaches for blockbuster drugs.

“The three of us are thrilled to join the dynamic team at Cooley and their acclaimed intellectual property litigation practice,” Shear, Flanagan and Biegler said. “We are looking forward to being a part of the firm’s collaborative culture and leveraging the firm’s dominant life sciences reputation to further enhance the practice.”

Offering a team of 65+ lawyers with significant experience representing clients in technology and life sciences matters, Cooley’s IP litigation practice is renowned for its ability to win bet-the-company competitor cases in which multibillion-dollar products, technologies and brands are at stake. Cooley boasts one of the most active patent litigation practices in the US, having handled 525+ patent cases and 70+ US Court of Appeals for the Federal Circuit patent appeals – the vast majority as the appellee – in the past five years.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.